A new study has criticized the Cancer Drugs Fund (CDF), a program set up by the UK government to facilitate access to oncology treatments unavailable through the National Health Service (NHS).
The study, published in the Annals of Oncology, was carried out by researchers from the London School of Hygiene & Tropical Medicine and King’s College London.
It found that the CDF was not good value for patients, or society. In addition, researchers say it may have resulted in patients suffering from toxic side effects.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze